Compare
CytoDyn Inc. vs Exicure, Inc. vs Edesa Biotech, Inc. vs Cellectar Biosciences, Inc.
| Latest fiscal year | CytoDyn Inc. CYDY | Exicure, Inc. XCUR | Edesa Biotech, Inc. EDSA | Cellectar Biosciences, Inc. CLRB |
|---|---|---|---|---|
| Year ended | 2026-05-31 | 2025-12-31 | 2025-09-30 | 2025-12-31 |
| Revenue | n/a | $0 | n/a | n/a |
| Revenue growth (YoY) | n/a | -100.0% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$42.70M | -$4.95M | -$7.19M | -$21.79M |
| EPS (Diluted) | -$0.03 | -$0.79 | n/a | -$8.35 |
| Operating cash flow | -$17.25M | -$8.55M | -$7.32M | -$23.12M |
| Free cash flow | n/a | -$8.56M | n/a | -$23.12M |
| Cash & equivalents | $11.85M | n/a | $10.80M | $13.20M |
| Total assets | $13.97M | $14.04M | $13.53M | $14.98M |
| Total liabilities | $123.69M | $10.12M | n/a | $5.06M |
| Shareholders' equity | -$109.72M | $3.93M | $12.45M | $8.54M |
| Return on year-end equity | n/a | -126.0% | -57.7% | -255.2% |
| Shares outstanding | 1.37B | 6.37M | 7.14M | 4.24M |
Revenue, most recent five fiscal years
| Fiscal year | CytoDyn Inc. | Exicure, Inc. | Edesa Biotech, Inc. | Cellectar Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2023-05-31 | $0 Ended 2025-12-31 | $0 Ended 2021-09-30 | n/a |
| 1 year earlier | $266.0K Ended 2022-05-31 | $500.0K Ended 2024-12-31 | $328.8K Ended 2020-09-30 | n/a |
| 2 years earlier | $0 Ended 2021-05-31 | $0 Ended 2023-12-31 | n/a | n/a |
| 3 years earlier | n/a | $28.83M Ended 2022-12-31 | $211.8K Ended 2018-09-30 | n/a |
| 4 years earlier | n/a | -$483.0K Ended 2021-12-31 | $228.3K Ended 2017-09-30 | n/a |